Clinical Trials Logo

Ischemic Stroke clinical trials

View clinical trials related to Ischemic Stroke.

Filter by:

NCT ID: NCT03843008 Not yet recruiting - Ischemic Stroke Clinical Trials

Melatonin in Acute Stroke

Start date: April 2019
Phase: N/A
Study type: Interventional

This study will measure Interleukin 6 (IL-6), a well-documented inflammatory biomarker that is increased in the acute phase of stroke, and to compare its levels after the administration of melatonin - a well-documented anti-inflammatory and anti-oxidant - that regulates circadian rhythm, which helps promote sleep.

NCT ID: NCT03833375 Recruiting - Clinical trials for Traumatic Brain Injury

Goals-of-Care Shared Decision Making for Surrogates of Severe Acute Brain Injury Patients

Start date: February 11, 2018
Phase: N/A
Study type: Interventional

Severe acute brain injury (SABI), including large artery acute ischemic stroke, intracerebral hemorrhage, and severe traumatic brain injury continue to be the leading cause of death and disability in adults in the U.S. Due to concerns for a poor long-term quality of life, withdrawal of mechanical ventilation and supportive medical care with transition to comfort care is the most common cause of death in SABI, but occurs at a highly variable rate (for example in Traumatic Brain Injury (TBI) 45-89%). Decision aids (DAs) are shared decision-making tools which have been successfully implemented and validated for many other diseases to assist difficult decision making. The investigators have developed a pilot DA for goals-of-care decisions for surrogates of SABI patients. This was developed through qualitative research using semi-structured interviews in surrogate decision makers of TBI patients and physicians. The investigators now propose to pilot-test a DA for surrogates of SABI patients in a feasibility trial.

NCT ID: NCT03827720 Not yet recruiting - Ischemic Stroke Clinical Trials

Early Feasibility Study of the SENSE Device

Start date: March 2019
Phase: N/A
Study type: Interventional

A single site, study of the SENSE device in up to 20 study subjects, (five healthy controls and five each with ICH, AIS with LVO and AIS without LVO) in whom SENSE can be applied within 24 hours of stroke symptom onset.

NCT ID: NCT03823274 Not yet recruiting - Ischemic Stroke Clinical Trials

Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients

Start date: February 1, 2019
Phase:
Study type: Observational [Patient Registry]

This cohort study will evaluate the relatiobship of stroke recurrence and anti-platelet resistance in ischemic stroke patients

NCT ID: NCT03819452 Completed - Ischemic Stroke Clinical Trials

Impact of Vitamin D on Acute Ischemic Stroke Prognosis

IVASTO
Start date: August 1, 2018
Phase:
Study type: Observational [Patient Registry]

This is a registry for all patients admitted to hospital settings with Ischemic stroke in Mansoura University Hospital. The registry will capture patients' data, investigations and vitamin D level on admission. Follow-up is taking place using MODIFIED RANKIN SCALE

NCT ID: NCT03815292 Recruiting - Clinical trials for Mild Cognitive Impairment

Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke

Start date: October 19, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is: - to assess efficacy of MMH-MAP in the treatment of mild cognitive impairment in early stage of recovery after ischemic stroke - to assess safety of MMH-MAP in the treatment of mild cognitive impairment in early stage of recovery after ischemic stroke

NCT ID: NCT03815175 Not yet recruiting - Clinical trials for Coronary Artery Disease

XIENCE 28 USA Study

Start date: March 30, 2019
Phase: N/A
Study type: Interventional

The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family (XIENCE Xpedition Everolimus Eluting Coronary Stent System [EECSS], XIENCE Alpine EECSS and XIENCE Sierra EECSS) of coronary drug-eluting stents.

NCT ID: NCT03812653 Not yet recruiting - Stroke Clinical Trials

Sleep for Stroke Management and Recovery Trial

Sleep SMART
Start date: March 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) improves stroke outcomes at 3 months in patients who experienced an ischemic stroke.

NCT ID: NCT03806894 Not yet recruiting - Ischemic Stroke Clinical Trials

Clopidogrel Resistance in Stroke Patients From Different Ethnicities

Start date: March 2019
Phase:
Study type: Observational

Clopidogrel is an anti-platelet agent used to inhibit blood clots. Variation in response to clopidogrel has been reported among different population and may lead to reoccurring ischemic events. The aim of the present study is to evaluate the incidence of clopidogrel resistance in ischemic stroke patients from different ethnicities in Northern Israel and to find different strategies to overcome high platelet reactivity including clopidogrel dose adjustment or the choice of alternative agents. Quantification of platelet aggregation will be determined by vasodilator stimulated phosphoprotein (VASP) assay.

NCT ID: NCT03805308 Not yet recruiting - Ischemic Stroke Clinical Trials

The TELSA Trial: Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke

TESLA
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

The primary objective of the trial is to establish the effectiveness of IAT (versus medical management) in patients with moderate-large infarcts (NCCT ASPECTS 2-5) at baseline, with adaptive enrichment to better define the upper limit of infarct volume for treatment eligibility. Furthermore, the investigators aim to determine whether certain subgroups of patients with large baseline infarcts will have a greater treatment benefit. Finally, the investigators will assess the agreement of ASPECTS scores between site investigators, the core imaging lab, and automated software.